Betaliq
Phase 3Founded in 2018 through a strategic collaboration between BLP Management Group and Novaliq GmbH, Betaliq is redefining topical ophthalmic therapies with a strong focus on safety, efficacy, and innovation. Through this partnership, we hold exclusive rights to Novaliq’s proprietary EyeSol® technology – a water-free drug delivery platform designed to optimize treatment outcomes – for glaucoma therapies. With a vision for expansion, Betaliq is well-positioned to build a portfolio of Glaucoma ther...
About
Founded in 2018 through a strategic collaboration between BLP Management Group and Novaliq GmbH, Betaliq is redefining topical ophthalmic therapies with a strong focus on safety, efficacy, and innovation. Through this partnership, we hold exclusive rights to Novaliq’s proprietary EyeSol® technology – a water-free drug delivery platform designed to optimize treatment outcomes – for glaucoma therapies. With a vision for expansion, Betaliq is well-positioned to build a portfolio of Glaucoma ther...
Funding History
1Total raised: $3.2M
Company Info
Contact
Sectors
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile